CanSino Biologics’ building in Tianjin, China. Photo: Reuters
CanSino Biologics’ building in Tianjin, China. Photo: Reuters
A-shares

China pharmaceutical maker CanSino rallies in Hong Kong and Shanghai trading after Covid-19 vaccine gets WHO approval

  • The move opens a door for the company’s one-dose Convidecia vaccine to enter the global market
  • CanSino shares slid at least 79 per cent over the past year amid increased competition and falling vaccine prices in China

CanSino Biologics’ building in Tianjin, China. Photo: Reuters
CanSino Biologics’ building in Tianjin, China. Photo: Reuters
READ FULL ARTICLE